Peanut Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

In Westernized countries, peanut allergy presents a mounting concern for public health. This allergy, often severe and lifelong, significantly impacts the quality of life and can induce anxiety. The primary risk of reaction arises from direct ingestion, whereas incidental skin contact or airborne exposure typically does not elicit significant symptoms. Symptoms of peanut allergy manifest across various bodily systems, including cutaneous (such as urticaria, erythema, and angioedema), gastrointestinal (involving abdominal pain, vomiting, and diarrhea), respiratory (marked by wheezing and dyspnea), and cardiovascular (potentially leading to hypotension, arrhythmia, and shock). The onset of symptoms typically occurs promptly following peanut ingestion, though biphasic reactions may occur, with exacerbations manifesting up to 8 hours later. Diagnosis of peanut allergy primarily relies on medical history, including dietary records and elimination diets, supplemented by skin testing, measurement of peanut-specific IgE levels, and, ideally, oral peanut challenges. Several immunotherapeutic approaches, including Oral Immunotherapy (OIT), Epicutaneous Immunotherapy (EPIT), and Sublingual Immunotherapy (SLIT), have emerged as potential treatments for peanut allergy. However, none of these interventions offer a perfect solution, each with its own advantages and disadvantages.
• Peanut allergy affects a notable portion of the pediatric population, ranging from 1% to 4.5%, with the potential for severe and life-threatening reactions.

Thelansis’s “Peanut Allergy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Peanut Allergy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Peanut Allergy across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Peanut Allergy Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Peanut Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033